Alendronate-induced auditory hallucinations and visual disturbances

Pharmacotherapy

Volumn 24, Issue 6, 2004, Pages 799-802

  Coleman, Craig I ^a,b   Perkerson, Kristen A ^a,b   Lewis, Anne ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Alendronate; Auditory hallucinations; Bisphosphonates; Visual disturbances

Indexed keywords

ALENDRONIC ACID; AMLODIPINE; BISACODYL; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; DOCUSATE SODIUM; ETIDRONIC ACID; FUROSEMIDE; GLUCOCORTICOID; LEVOTHYROXINE; METOPROLOL; PAMIDRONIC ACID; PRAVASTATIN; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

AGED; ALGORITHM; AMNESIA; ARTICLE; AUDITORY HALLUCINATION; BLEEDING; CALCIUM HOMEOSTASIS; CASE REPORT; CENTRAL NERVOUS SYSTEM; CONFUSION; DELUSION; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DYSPEPSIA; DYSPNEA; ESOPHAGUS ULCER; EYE DISEASE; FATIGUE; FEMALE; HALLUCINATION; HEART PALPITATION; HUMAN; HYPOCALCEMIA; IRRITABILITY; MUSCLE SPASM; NARANJO AND JONES ALGORITHM; NAUSEA; NEUROTOXICITY; OLFACTORY HALLUCINATION; OSTEOPOROSIS; SIDE EFFECT; SKIN TINGLING; VISUAL DISORDER;

AGED; ALENDRONATE; FEMALE; HALLUCINATIONS; HUMANS; OSTEOPOROSIS; VISION DISORDERS;

EID: 2942625483     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.8.799.36062     Document Type: Article

References (15)

1. Merck and Co., Inc. Fosamax (alendronate) package insert. Whitehouse Station, NJ; 2003.
2. Aventis Pharmaceuticals, Inc. Actonel (risedronate) package insert. Kansas City, MO; 2003.
3. Sanofi-Synthelabo, Inc. Skelid (tiludronate) package insert. New York, NY; 2002.
4. Procter & Gamble Pharmaceuticals. Didronel (etidronate) package insert. Cincinnati, OH; 2003.
5. Novartis Pharmaceuticals. Aredia (pamidronate) package insert. East Hanover, NJ; 2003.
6. Novartis Pharmaceuticals. Zometa (zoledronic acid) package insert. East Hanover, NJ; 2003.
7. Body JJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 2001;28(4 suppl 11):49-53.
8. Cryer R, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002;77:1031-43.
9. Burnet SP, Petrie JP. Wake up and smell the roses: a drug reaction to etidronate [letter]. Aust N Z J Med 1999;29:93.
10. Foley-Nolan D, Daly MJ, Williams D, Wasti A, Martin M. Pamidronate-associated hallucinations [letter]. Ann Rheum Dis 1992;51:927-8.
11. Schultz NJ, Chitwood-Dagner KK. Body electrolyte homeostasis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. Stamford, CT: Appleton & Lange, 1993:1105-38.
12. Rey J, Daumen-Legre V, Pharm T, et al. Uveitis, an under-recognized adverse effect of pamidronate: case report and literature review. Joint Bone Spine 2000;67:337-40.
13. Lantz MS, Giambanco V. Acute onset of auditory hallucinations after initiation of celecoxib therapy [letter]. Am J Psych 2000;157:1022-3.
14. Naranjo CA, Busto A, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
15. Jones JK. Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Fam Community Health 1982;5:58-67.